But one high-risk population remains systematically overlooked in many testing advances: people with Down syndrome. Alzheimer’s incidence is dramatically higher in this group, yet key biomarker assays often lack validation specifically tailored to their biology. Without population-specific evidence, clinicians and families face uncertainty when symptoms overlap with other neurodevelopmental or age-related conditions.

A new USC-led study, published in Communications Medicine, addresses that gap. Researchers evaluated two blood-based biomarkers—Lumipulse G p-tau217/β-Amyloid 1-42 and PrecivityAD2—in participants with Down syndrome. Notably, Lumipulse G received FDA approval in 2025 to support Alzheimer’s diagnosis in the general population, but it had not been studied in Down syndrome until now.

The study enrolled 39 participants with Down syndrome. Each participant provided blood for both assays and underwent amyloid PET imaging, considered a reference standard for detecting brain amyloid pathology. The investigators reported that both blood tests reliably identified abnormal amyloid burden in the brain.

Using advanced statistical methods, the team derived preliminary diagnostic thresholds for Down syndrome. These cutoffs separated individuals with versus without Alzheimer’s pathology with accuracy comparable to what is observed in broader populations. In other words, the biomarker signal behaves in a way that can be translated into clinically actionable decision-making.

Beyond detection, the work suggests a workflow similar to general-population strategies: a positive blood result could be used to guide confirmation and downstream evaluation, while the blood test’s low false-negative rate supports its utility as an earlier screening layer.

Such screening has practical implications for families. Ruling out Alzheimer’s pathology may redirect clinicians toward other plausible drivers of cognitive or behavioral decline, including treatable medical conditions. It also strengthens trial recruitment by enabling biomarker-based eligibility selection.

The team plans further validation in a larger Down syndrome cohort. In parallel, the results are already poised to accelerate research, including an upcoming clinical trial of donanemab in people with Down syndrome, using elevated amyloid measured from blood to select participants.

Subject of Research: People with Down syndrome (Alzheimer’s biomarkers)
Article Title: Exploring automated plasma phospho-tau217 assays for the diagnosis of Down syndrome-related Alzheimer’s disease
News Publication Date: 2-Jun-2026
Web References: https://www.nature.com/articles/s43856-026-01709-0
References: 10.1038/s43856-026-01709-0
Image Credits:
Keywords: Alzheimer’s disease, Down syndrome, plasma biomarkers, p-tau217, amyloid, Lumipulse G, PrecivityAD2, PET imaging, early diagnosis, clinical trials

The journey into the olfactory cleft—an area at the upper part of the nasal cavity—serves as a unique window into the pathological processes of Alzheimer’s disease. Unlike traditional methods relying heavily on invasive brain biopsies or costly neuroimaging techniques, this biopsy approach taps into a more accessible anatomical site. The olfactory region, being one of the first areas affected by Alzheimer’s pathology, presents an untapped reservoir of biomarkers that reflect the brain’s biochemical milieu during disease progression.

Olfactory dysfunction has long been associated with Alzheimer’s, but until now, the pathological signatures within the olfactory cleft remained largely unexplored. The team led by D’Anniballe, Kim, and Finlay employed cutting-edge histological, biochemical, and molecular analyses on tissue samples obtained via minimally invasive nasal biopsies. Their goal was to map the trajectory of hallmark Alzheimer’s pathologies—specifically amyloid-beta plaques, tau protein tangles, and neuroinflammation—within the olfactory epithelia and adjacent structures.

One of the most striking findings demonstrates a clear correlation between the abundance of amyloid-beta deposits in the olfactory cleft and the severity of cognitive decline. This provides compelling evidence that changes in the olfactory mucosa mirror those in critical brain regions traditionally associated with memory and cognition, such as the hippocampus and entorhinal cortex. Intriguingly, amyloid accumulation in the olfactory tissues was detectable even in preclinical stages when cognitive symptoms are subtle or absent, highlighting a powerful predictive biomarker potential.

Equally remarkable was the observation of tau protein aggregation within the olfactory neurons. The pathological tau species detected bear close resemblance to those forming neurofibrillary tangles in brain tissue, confirming the olfactory cleft as an active site of Alzheimer’s disease pathology, not just a passive victim of degeneration. This tau pathology correlated with olfactory dysfunction severity, providing a mechanistic link between sensory loss and molecular changes within the disease cascade.

Beyond amyloid and tau, the neuroinflammatory milieu was comprehensively profiled, unveiling elevated microglial activation and cytokine expression in olfactory regions from Alzheimer’s patients. This aspect of the research underscores the olfactory cleft as an immunological nexus, where chronic inflammation might drive or exacerbate neurodegenerative processes. Such findings add layers of complexity and nuance to Alzheimer’s pathobiology, shifting the paradigm toward multisystem involvement rather than isolated brain pathology.

The methodology leveraged in this study represents a significant leap forward. By integrating immunohistochemistry, advanced imaging techniques, and transcriptomic analyses, the researchers managed to paint a multi-dimensional picture of disease evolution—capturing not only structural but also molecular dynamics. This robust approach allowed for differentiation of Alzheimer’s stages based on olfactory tissue profiles, setting the stage for staging disease progression through relatively non-invasive means.

Crucially, the team validated their biomarker discoveries against established clinical assessments, including cognitive testing and neuropsychological measures. Correlations between olfactory biopsy findings and clinical staging were statistically robust, supporting the feasibility of this approach in real-world diagnostic settings. The prospect of utilizing a simple nasal biopsy to detect and monitor Alzheimer’s introduces a potentially transformative paradigm shift in patient care, enabling earlier intervention and personalized disease management.

This study also highlights the importance of the olfactory system in neurodegenerative research more broadly. Olfaction is one of the earliest sensory domains to decline in Alzheimer’s and several other dementias, yet it has been significantly underrepresented in biomarker discovery pipelines. The research not only bridges this gap but also provides a practical framework for future exploration of sensory system pathologies as windows into brain health.

Furthermore, the implications extend beyond diagnostics. Understanding the molecular mechanisms underpinning olfactory pathology could unveil novel therapeutic targets. Interventions aimed at modulating amyloid or tau accumulation specifically within the olfactory system, or attenuating local inflammation, may hold promise in slowing disease progression or alleviating some early symptoms.

The study’s success also underscores the power of interdisciplinary collaboration, merging neurology, pathology, molecular biology, and olfactory science. This integrated approach charted new territory in our comprehension of Alzheimer’s disease and exemplified how harnessing diverse scientific expertise can crack open longstanding medical enigmas.

For clinicians and caregivers, these findings provide renewed hope. The debilitating impact of Alzheimer’s, particularly the debilitating loss of memories and autonomy, demands urgently improved tools for early diagnosis and monitoring. The olfactory cleft biopsy method could be rapidly incorporated into clinical workflows, complementing existing neuroimaging and cerebrospinal fluid analyses, and making comprehensive biomarker assessment more accessible.

As the global population ages, the societal burden of Alzheimer’s disease only intensifies. Innovations such as this set the foundation for public health strategies aimed at early detection and potentially preventative treatments. Moreover, widespread adoption of such diagnostic tools might recalibrate clinical trial design by enabling better participant stratification according to molecular disease burden, speeding up the development of effective therapeutics.

Looking ahead, further research will be essential to refine biopsy techniques, optimize molecular assays, and validate these findings in larger, more diverse populations. Longitudinal studies tracking olfactory pathology over time will illuminate the temporal dynamics of Alzheimer’s progression and clarify how early interventions might modify disease trajectories.

In conclusion, the pioneering analysis of the olfactory cleft as documented by D’Anniballe and colleagues marks a milestone in Alzheimer’s disease research. It breaks new ground by revealing that the molecular fingerprints of this complex disorder are detectable, quantifiable, and clinically meaningful within the realm of olfactory tissues. This work not only advances scientific knowledge but also charts a hopeful path toward earlier diagnosis, better patient outcomes, and ultimately, a deeper understanding of the mechanisms driving one of humanity’s most challenging neurological diseases.

Subject of Research:
Alzheimer’s disease pathobiology through analysis of olfactory cleft biopsies.

Article Title:
Olfactory cleft biopsy analysis of Alzheimer’s disease pathobiology across disease stages.

Article References:
D’Anniballe, V.M., Kim, S., Finlay, J.B. et al. Olfactory cleft biopsy analysis of Alzheimer’s disease pathobiology across disease stages. Nat Commun 17, 2245 (2026). https://doi.org/10.1038/s41467-026-70099-7

Image Credits:
AI Generated

DOI:
https://doi.org/10.1038/s41467-026-70099-7